Broker recommendations for Johnson & Johnson
The Johnson & Johnson stock is rated at 1.333333 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Sunday 26 July, 2020 by a total of 18 brokers. This means that the consensus of the 18 different brokers is leaning toward to buy/moderate buy.
0 (0%) Underweight
0 (0%) Hold
5 (27.78%) Overweight
2 (11.11%) Buy
EU to Buy 200 Million Doses of the Potential COVID-19 Vaccine From Johnson & Johnson
Friday, 14 August 2020, 00:33:45
The European Commission has concluded exploratory talks with Johnson & Johnson to buy 200 million doses of a potential COVID-19 vaccine, the EU executive and the U.S. pharmaceutical company said on Thursday. The EU executive arm said this paved the way for contractual talks and the possible purchase of the vaccine on behalf of all 27 EU states once it has proven safe and effective. The commission also said it could purchase an additional 200 million vaccine doses. Johnson & Johnson, through its Belgian subsidiary Janssen, “will now enter into contract negotiations with the European Commission,” J&J said in a statement, confirming the volumes indicated by the Commission. “If regulatory approval for the company’s vaccine is received, the Commission would be expected to facilitate a process for allocation of the vaccine doses among the member states,” Johnson & Johnson said. J&J could produce up to 1 billion doses of its vaccine by the end of 2021, a company executive told Reuters on Tuesday.
EU Secures 200M Doses Of Johnson & Johnson’s Covid-19 Vaccine Candidate
Thursday, 13 August 2020, 20:44:08
The European Commission announced Thursday that it has concluded exploratory talks with US pharmaceutical company Johnson & Johnson to secure the initial purchase … The post EU Secures 200M Doses Of Johnson & Johnson’s Covid-19 Vaccine Candidate appeared first on Smarter Analyst .
— Smarter Analyst
EU reserves 400 million doses of potential J&J virus vaccine
Thursday, 13 August 2020, 20:38:41
Brussels, Belgium — The European Union said Thursday it had reserved up to 400 million doses of a potential new coronavirus vaccine being developed by US giant Johnson & Johnson. Preliminary talks concluded Friday for the first purchase of 200 million doses followed by an equal number later, a statement said. “The envisaged contract with Johnson & Johnson would provide for the possibility for all EU Member States to purchase the vaccine, as well as to donate to lower and middle-income countries,” it said. The bloc said it was in “intensive discussions” with other manufacturers for potential vaccines. According to the World Health Organization, nearly 3.7 million cas… Keep on reading: EU reserves 400 million doses of potential J&J virus vaccine
— Inquirer News Info
10 healthcare startups that could be M&A targets after Teladoc’s record-breaking $18.5 billion deal for Livongo
Thursday, 13 August 2020, 17:53:53
On August 5, telehealth giant Teladoc struck an $18.5 billion deal to buy Livongo , a chronic-care company. The record deal is sending shockwaves through an industry that analysts say is ripe for more mergers and acquisitions. Business Insider asked 10 venture capitalists and analysts about the impending consolidation in digital health. They listed 10 startups in mental health, drug research, telehealth, and more that are likely to be acquired or make deals of their own soon. For more stories like this, sign up here for our healthcare newsletter, Dispensed . On August 5, telehealth giant Teladoc struck an $18.5 billion deal to buy Livongo , a chronic-care company. It’s the biggest deal in digital health history, and it’s sending shockwaves through an industry that’s ripe for more mergers and acquisitions, according to Rock Health, a digital health venture fund and advisory firm. “This announcement is merely the starter’s pistol for an inevitable virtual care platforms race,” wrote Sari Kaganoff, a general manager at Rock Health, in a report on August 6 .
— Business Insider
Indian drugmaker Biological E. to make substance used in J&J’s potential COVID-19 vaccine
Thursday, 13 August 2020, 14:03:36
Indian drugmaker Biological E. Ltd will begin making a drug substance used in Johnson & Johnson’s COVID-19 vaccine candidate that is in early to mid-stage trials, the companies said on Thursday.